Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer

NCT06711471 · clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
31
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

LIN YANG